| ORIGINAL ARTICLE |
|
| Year : 2017 | Volume
: 4
| Issue : 2 | Page : 46-48 |
|
|
A study on evaluation of bevacizumab in the management of diabetic retinopathy
Mohammad Jaffar Sadiq1, Alsayed Ahmed Zaki1, B. Siva Prakash Rao2, P Vaasanthi3, K Thriveni3, P Siva Prasad3, J Thippe Rudra3, Faisal Imran4
1 Department of Clinical Pharmacology, Batterjee Medical College, North Obhur, Jeddah 21442, Kingdom of Saudi Arabia
2 Department of Ophthalmologist, Prakash Eye Hospital, Sainagar, India
3 Pharm D Intern, Raghavendra Institute of Pharmaceutical Education and Research, Ananthapuramu, Andhra Pradesh, India
4 Department of Quality and Development, Batterjee Medical College, North Obhur, P.O. 6231, Jeddah 21442, Kingdom of Saudi Arabia
Correspondence Address:
Mohammad Jaffar Sadiq
Department of Clinical Pharmacology, Batterjee Medical College, North Obhur, P.O. 6231, Jeddah 21442
Kingdom of Saudi Arabia
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/erj.erj_6_17
|
|
|
Aims: The study stands to evaluate the usage of bevacizumab against diabetic retinal neovascularisation. Materials and Methods: The outcome measures of study include the determination of visual acuity and retinal cum macular thickness after bevacizumab administration. Twenty diabetic retinopathy patients were screened for bevacizumab administration and given either one or two doses of bevacizumab. Patient's visual acuity and optical tomography's results were analyzed to determine the vision, retinal, and macular thickness. Statistical Analysis Used: The numeric results were passed through analysis of variance, employing “Student's t-test” as posttest for statistically determining the numeric outcomes. Results: Within 1 month of bevacizumab administration visual acuity (distant vision, near vision, and pinhole vision) was improved to logarithm of the minimum angle of resolution (MAR) 0.63 ± 0.07 from 0.87 ± 0.12 of distant vision. Pinhole vision was improved to log MAR 0.37 ± 0.06 from 0.478 ± 0.07 and near vision was improve to log MAR 0.477 ± 0.071 from 0.528 ± 0.069, and retinal thickness was decreased to 336 ± 17.35 μm from 429 ± 30.20 μm. Mean macular thickness was improved to 363.75 ± 24.54 μm from 452.37 ± 30.99 μm. Conclusion: Hence, the off-label use of bevacizumab for the said treatment may be proven beneficial.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
